Pulmonary Hypertension Prevention in Hemodialysis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2011 by The Baruch Padeh Medical Center, Poriya.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
The Baruch Padeh Medical Center, Poriya
ClinicalTrials.gov Identifier:
NCT01350687
First received: May 8, 2011
Last updated: May 9, 2011
Last verified: April 2011
  Purpose

Pulmonary hypertension is a new complication described in hemodialysis patients. in the last year these patients were treated by calcium carbonate orally to control serum phosphor. Calcium phosphor deposits in pulmonary artery can explain this phenomena. The investigators want to investigate the new phosphor non calcium containing agents in hemodialysis patients and to measure the pulmonary pressure.


Condition
Chronic Kidney Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: New Phosphore Binders in Prevention of Pulmonary Hypertension

Resource links provided by NLM:


Further study details as provided by The Baruch Padeh Medical Center, Poriya:

Estimated Enrollment: 40
Study Start Date: June 2011
Estimated Study Completion Date: June 2014
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Detailed Description:

The investigators will measure pulmonary blood pressure before and after treatment with new phosphor binders, non calcium containing.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

40 patients on hemodialysis treated with Phosphore biders, non-calcium containig.

Criteria

Inclusion Criteria:

  • Hemodialysis Patients without fistula

Exclusion Criteria:

  • Heart Disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01350687

Locations
Israel
Poria Medical Center Not yet recruiting
Tiberias, Israel
Contact: Farid Nakhoul, Prof    97246652587    fnakhoul@poria.health.gov.il   
Principal Investigator: Farid Nakhoul, Prof         
Sponsors and Collaborators
The Baruch Padeh Medical Center, Poriya
Investigators
Study Chair: Farid Nakhoul, Prof. Poria medical Center
  More Information

No publications provided

Responsible Party: Avi On, Poria Medical Center
ClinicalTrials.gov Identifier: NCT01350687     History of Changes
Other Study ID Numbers: farid.CTIL
Study First Received: May 8, 2011
Last Updated: May 9, 2011
Health Authority: Israel: The Israel National Institute for Health Policy Research and Health Services Research

Keywords provided by The Baruch Padeh Medical Center, Poriya:
Calcium Phosphore
Renagel

Additional relevant MeSH terms:
Hypertension
Renal Insufficiency, Chronic
Kidney Diseases
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Renal Insufficiency
Urologic Diseases
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on October 19, 2014